Tulathromycin accumulates in target tissues such as neutrophils and alveolar macrophages, followed by a slow release, maintaining effective drug concentrations for a prolonged period. Due to its pharmacokinetic profile of lung-targeted accumulation, tulathromycin is clinically beneficial for the prevention and treatment of upper respiratory tract diseases, achieving excellent therapeutic efficacy after a single dose.
It can be used to treat and prevent bovine respiratory diseases caused by Pasteurella multocida, Pasteurella multocida, Haemophilus somnus, and Mycoplasma; and to treat and prevent porcine respiratory diseases caused by Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma pneumoniae, and Haemophilus parasuis.
